Nab-paclitaxel plus sintilimab as second-line therapy for advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJA): Preliminary results from an open-label, single-arm, phase 2 study.Zhichao Jiang, Aiping Zhou, Wen Zhang et al.|Journal of Clinical Oncology|2022Cited by 2
Treatment modalities of regorafenib and survival in metastatic colorectal (mCRC) patients: A real-world multicenter retrospective study.Wang Qu, Aiping Zhou, Zimin Liu et al.|Journal of Clinical Oncology|2023Cited by 1
Updated results and biomarker analyses from the phase 2 trial of nab-paclitaxel plus sintilimab as second-line therapy for advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (G/GEJA).Zhichao Jiang, Aiping Zhou, Wen Zhang et al.|Journal of Clinical Oncology|2024Cited by 1
Regorafenib monotherapy as the later-line treatment for elderly patients with metastatic colorectal cancer: a multicenter real-world studyJinglong Huang, Aiping Zhou, Nan Zun Teo et al.|Journal of Gastrointestinal Oncology|2024Cited by 1
Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.Zhichao Jiang, Aiping Zhou, Wei Deng et al.|Journal of Clinical Oncology|2022Cited by 0